Skip to main content
. 2020 Nov 25;40(11):BSR20193053. doi: 10.1042/BSR20193053

Figure 3. Atorvastatin inhibits miR-221 and promotes VEGFA expression to regulate EPC proliferation and migration.

Figure 3

(A,B) Immunoblotting to quantitate VEGFA protein levels of EPCs transfected with miR-221 mimics with or without atorvastatin (Ato) treatment; (C) MTT cell viability assays; (D) Transwell cell migration assays; (E) Tube formation assay to assess angiogenic capacity. *P<0.05, **P<0.01, compared to control group. #P<0.05, ##P<0.01, compared to Ato treatment group.